Mercurna moves to a new laboratory

Oss, the Netherlands, October 25th, 2019 – To provide proper accommodation for its ambitions, Mercurna, a pre-clinical-stage biotechnology company developing a platform for life-changing medicines based on messenger RNA (mRNA), has moved its operations to a new, larger laboratory at the Pivot Park Life-sciences campus.

The 135 m2 laboratory is equipped with all infrastructure to further develop Mercurna’s proprietary platform technology for mRNA-based drugs and advance the development of multiple lead-formulations based on this platform. Currently, Mercurna pipeline contains 3 active programs, including drug candidates for chronic kidney disease, kidney transplantation and an undisclosed ophthalmic indication. “We are very happy that the Pivot Park provides us with laboratory space solutions tailored to our needs and in addition provides us with a perspective for further expansion in the future”, says Sander van Asbeck, CEO of Mercurna.

The strategic position on the Pivot Park allows for collaborations with key players in the biotech value chain. Besides the location in Oss, Mercurna maintains a strong presence in Nijmegen, in light of its continued collaborations with several strategic partners there.

More information on the Pivot Park: https://www.pivotpark.com/